Medical Oncology

Medical Oncology Trials

ADRENOCORTICAL

FIRM-ACT
FIRST INTERNATIONAL RANDOMISED TRIAL IN LOCALLY ADVANCED AND METASTATIC ADRENOCORTICAL CARCINOMA TREATMENT

ANTIEMETIC

ANTIEMETIC INCIDENCE
INCIDENCE OF AND FACTORS AFFECTING NAUSEA AND VOMITING IN PATIENTS TAKING ORAL CHEMOTHERAPY AT HOME

SCH 619734
DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED SCH 619734 VERSUS PLACEBO FOR THE PREVENTION OF CHEMO INDUCED NAUSEA AND VOMITING IN CANCER PTS RECEIVING HIGHLY EMETOGENIC CHEMO

BLADDER

CA183002 BLADDER
MULTICENTRED RANDOMISED DOUBLE BLIND PHASE III STUDY IN FIRST LINE TREATMENT OF ADVANCED TRANSITIONAL CELL CARCINOMA (TCC) OF THE UROTHELIUM COMPARING VINFLUNINE/GEMCITABINE TO PLACEBO/GEMCITABINE IN PTS WHO ARE INELIGIBLE TO RECEIVE CISPLATIN BASED THERAPY

BREAST

A6181064
A RANDOMISED PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VS DOCETAXEL IN THE FIRSTLINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS

A6181107
PHASE III RANDOMISED, MULTICENTRED STUDY OF SUNITINIB (SU11248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER AFTER FAILURE OF PRIOR TAXANE AND ANTHRACYCLINE THERAPIES

A6181114
AN OPEN LABEL SUNITINIB (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENT

ATHENA
OPEN LABEL STUDY OF BEVACIZUMAB (AVASTIN) PLUS TAXANE MONOTHERAPY OR IN COMBINATION FOR FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER

BIG 2-06 ALTTO
A RANDOMISED, MULTI CENTRED, OPEN LABEL, PHASE III STUDY OF ADJUVANT LAPATINIB, TRASTUZUMAB, THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ERB/ERB2 POSITIVE PRIMARY BREAST CANCER. ALTTO (ADJUVANT LAPATINIB AND OR TRASTUZUMAB OPTIMISATION STUDY) BIG 2-06/N06D/EGF106708

IBCSG 34-05
PHASE II TRIAL OF LHRH ANOLOGUE ADMINISTRATION DURING CHEMOTHERAPY TO REDUCE OVARIAN FAILURE FOLLOWING STANDARD ADJUVANT CHEMOTHERAPY IN EARLY STAGE HORMONE RECEPTOR NEGATIVE BREAST CANCER

METASTATIC BREAST STUDY
A RESEARCH STUDY TO EVALUATE THE KINETICS OF MOBILISATION OF BLOOD STEM CELLS AND CIRCULATING TUMOUR CELLS IN RESPONSE TO DOCETAXEL CHEMOTHERAPY AND PEGFILGRASTIM

COLON

A0081124
A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE PREVENTION AND TREATMENT OF CHEMO INDUCED PERIPHERAL NEUROPATHY IN COLORECTAL CANCER - DUKES C OR D

QUASAR 2
MULTINATIONAL INTERNATIONAL STUDY OF CAPECITABINE +/- BEVACIZUMAB AS ADJUVANT TREATMENT OF COLON CANCER

RIFAMPICIN STUDY
RIFAMPICIN AS A PREDICTOR OF IRINOTECAN TOXICITY

LUNG

COVERT
NAVELBINE ORAL, CISPLATIN AND CONCURRENT RADIOTHERAPY FOLLOWED BY CONSOLIDATION IN THE TREATMENT OF INOPERABLE STAGE III NON-SMALL CELL LUNG CANCER PATIENTS

CRAD001C2114
A 2 STEP PHASE I STUDY INVESTIGATING THE COMBINATION OF RAD001 WITH CARBOPLATIN, PACLITAXEL AND BEVACIZIMUB IN PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS NOT PREVIOUSLY TREATED WITH SYTEMIC THERAPY

CRAD001C24115
PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF EVEROLIMUS WITH LETROZOLE FOR MANAGEMENT OF ADVANCED NON SMALL CELL LUNG CANCER AFTER FAILURE OF PLATINUM BASED TREATMENT

H3E-MC-JMHO
RANDOMISED PHASE III TRIAL OF ALIMTA (PEMETREXED) AND CARBOPLATIN IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

SAT2-05-07
RANDOMISED PHASE II COMPARING SEQUENTIAL SATRAPLATIN AND ERLOTINIB TO SINGLE AGENT ERLOTINIB IN PATIENTS >70 YEARS OF AGE WITH STAGE 3 OR 4 NSCLC AS 1ST LINE

MELANOMA

JZAF
A PHASE 2 STUDY OF LY573636 ADMINISTERED AS AN INTRAVENOUS INFUSION EVERY 21 DAYS AS SECOND-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

MELAN-A.A2 ANALOGUE
REVERSAL OF MELANOMA ANTIGEN SILENCING IN A PEPTIDE THERAPEUTIC MELANOMA VACCINE STUDY USIING NTERFERON-BETA

STA-4783-08
A RANDOMIZED DOUBLE BLIND PHASE III STUDY OF STA-4783 IN COMBINATION WITH PACLITAXEL VS PACLITAXEL ALONE FOR TREATMENT OF CHEMOTHERAPY NAÏVE SUBJECTS WITH STAGE IV METASTATIC MELANOMA

MUCOSITIS

BURDEN OF ILLNESS
RISK AND OUTCOMES OF MUCOSITIS IN SUBJECTS BEING TREATED FOR BREAST, COLORECTAL, HEAD & NECK, NON SMALL CELL LUNG, ORAL CAVITY / OROPHARYNX, HYPOPHARYNX / LARYNX CANCERS

GUT HEALTH IN PATIENTSb
THE SUCROSE BREATH TEST AS AN INDICATOR OF GUT WITH CANCER DAMAGE IN PATIENTS WITH CANCER

NESTEC REC1644
ASSSESSMENT OF AN ORAL SUPPLEMENT IN ADULT CANCER PATIENTS WITH MUCOSITIS REC1644

PANCREAS

GOFURTGO
PHASE II STUDY OF FIXED DOSE RATE GEMCITABINE-OXALIPLATIN INTEGRATED WITH CONCOMITANT 5FU AND 3-D CONFORMAL RADIOTHERAPY FOR THE TREATMENT OF LOCALISED PANCREATIC CANCER

PROSTATE

20050147
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI CENTRE PHASE 3 STUDY OF DENOSUMAB ON PROLONGING BONE METASTASES FREE SURVIVAL IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER

RENAL

A6181110
PHASE II EFFICACY AND SAFETY STUDY OF SU11248 IN PATIENTS WITH ADVANCED (FIRST LINE) RENAL CELL CANCER

3066K1-404-WW
A RANDOMISED TRIAL OF TEMSIROLIMUS AND SORAFENIB AS SECONDLINE THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAVE FAILED FIRST LINE SUNITINIB THERAPY

SORCE
A PHASE III RANDOMISED DOUBLE BLIND STUDY COMPARING SORAFENIB WITH PLACEBO IN PATIENTS WITH RESECTED PRIMARY RENAL CELL CARCINOMA AT HIGH OF INTERMEDIATE RISK OF RELAPSE

TESTES

BEP
PHASE II TRIAL OF ACCELERATED BEP AS FIRST LINE CHEMOTHERAPY IN ADVANCED GERM CELL TUMOURS

CHEMO AND COGNITION
COGNITIVE FUNCTION AND TREATMENT FOR TESTICULAR CANCER

SUPPORTIVE STUDIES/OTHER

ENHANCING INFORMED CONSENT
EVALUATION OF A CONSENT QUESTION PROMPT LIST IN CANCER CLINICAL TRIALS

IMPACT
A PROSPECTIVE OBSERVATIONAL STUDY REVIEWING NEUTROPENIA AND ANAEMIA RISK MANAGEMENT IN SUBJECTS WITH SOLID TUMOURS RECEIVING MYELOTOXIC CHEMOTHERAPY

INFLUENZA ANTIBODY
A STUDY TO EVALUATE ANTIBODY RESPONSES TO INFLUENZA VACCINE IN PANCREATIC CANCER PATIENTS RECEIVING GEMCITABINE CHEMOTHERAPY.

QUALITY OF LIFE AND SPIRITUAL WELL-BEING
A STUDY OF QUALITY OF LIFE AND SPIRITUAL WELL-BEING IN PATIENTS WITH CANCER